1. Is Elder Pharmaceuticals Ltd. a good quality company?
Data is not available for this company.
2. Is Elder Pharmaceuticals Ltd. undervalued or overvalued?
No data found
3. Is Elder Pharmaceuticals Ltd. a good buy now?
No data found
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||9.9%||11.9%||12.6%||13.3%||10.1%||10.2%||9.9%||10.3%||11.1%||-3.6%||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||24.4%||26.6%||22.7%||12.5%||13.4%||19.3%||17.4%||0.2%||-51%||-|
|Adj EPS ⓘ||12||21.1||28.4||36.6||27.4||31.2||36.2||43.2||37.6||-117.8||-30.2|
|YoY Gr. Rt. %||-||75.7%||35%||28.6%||-25.2%||14.2%||15.9%||19.3%||-12.9%||-413.1%||-|
|BVPS (₹) ⓘ||124.2||146.3||172.8||203.9||220.2||251.7||297.6||336.8||303||382.5||299.2|
|Adj Net Profit ⓘ||19.2||36.8||52.8||68.8||51.6||58.9||74.3||88.6||77.3||-242||-62|
|Cash Flow from Ops. ⓘ||-10.3||-5.3||70.9||-37.4||62.2||8.9||61.8||19.5||-25.5||1,153||-|
|Debt/CF from Ops. ⓘ||-12.8||-37.6||3.3||-9.1||6.4||62.2||12.1||45.4||-35.7||0.5||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||-228.9%||-233.9%||-248.2%||-413.1%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||12.6||16.1||18.2||19.4||12.9||13.2||13.7||13.6||13.1||-30.9||-8.9|
|Op. Profit Mgn % ⓘ||14.7||17.1||17.4||19.1||16.3||18.4||21||20.6||21.8||-13.4||-95.3|
|Net Profit Mgn % ⓘ||6.7||10.4||11.8||12.5||8.3||8.4||8.9||9||7.8||-50||-26.7|
|Debt to Equity ⓘ||0.7||0.8||0.7||0.9||1||1.2||1.2||1.3||1.5||0.8||-|
|Working Cap Days ⓘ||261||243||231||212||232||250||257||281||327||755||0|
|Cash Conv. Cycle ⓘ||148||143||132||109||117||132||137||147||122||179||0|
No data to display
Return on Equity has declined versus last 3 years average to %
Sales growth has been subdued in last 3 years %
Sales growth is not so good in last 4 quarters at %
|TTM EPS (₹)||-30.2||-38.9|
|TTM Sales (₹ Cr.)||233||631|
|BVPS (₹.) ⓘ||299.2||319.6|
|Reserves (₹ Cr.) ⓘ||594||636|
|From the Market|
|52 Week Low / High (₹)||37.10 / 38.00|
|All Time Low / High (₹)||20.35 / 474.00|
|Market Cap (₹ Cr.)||78|
|Equity (₹ Cr.)||20.5|
|Face Value (₹)||10|
|Industry PE ⓘ||35.8|
Elder Pharmaceuticals was incorporated in the year 1983 and commenced operations in 1989. The company is engaged into manufacturing and marketing of prescription pharmaceutical brands, surgical and medical devices.
Elder is one the leading companies in the pharmaceutical formulation market in India. It holds market leader position in three therapeutic segments - Womenâ€™s Healthcare, Wound Care and Nutraceuticals.
Elder manufactures API and formulations spread across 4 manufacturing plants in India and one in Nepal. It manufactures various dosage forms like tablets, capsules, syrups, injectables, topical creams and ointments.
It manufactures wide range of pharmaceutical brands such as Thrive G, Formic, Carnitor, Tanatril, B-long, Cranbe, Bonviva etc.
Company Shelcal brand is one of the top brands in the Indian pharmaceutical industry.
The company was awarded Amity Corporate Excellence Award for the year 2008
Elder was also honoured Frost & Sullivan Market Leadership Award for its 'Shelcal' brand for the year 2008.
It was among the Forbes list of 'Asia's 200 Best under a billion' over a period of three years.
It has subsidiary namely Elder International FZCO in Dubai, Somerta Holdings Company in Cyprus and Elder Biomeda EDA in Bulgaria.
In 2012 - Joint Managing Director Mr Alok Saxena has been bestowed with â€œBrand Slam Leadership Awardâ€ on 13th Oct, 2012 by Indira Group of Institutes, Pune.
- Elder Pharma is awarded India's Most Admired Nutrition and Neutraceutical Company of the Year 2012
-Elder Pharmaceuticals Limited is awarded with CIO100 Award.
-Elder Pharma join hands with Swedish firm Sterisol AB